IN2012DN05099A - - Google Patents

Download PDF

Info

Publication number
IN2012DN05099A
IN2012DN05099A IN5099DEN2012A IN2012DN05099A IN 2012DN05099 A IN2012DN05099 A IN 2012DN05099A IN 5099DEN2012 A IN5099DEN2012 A IN 5099DEN2012A IN 2012DN05099 A IN2012DN05099 A IN 2012DN05099A
Authority
IN
India
Prior art keywords
active agents
delivery compositions
conjugated
charge
polymer
Prior art date
Application number
Other languages
English (en)
Inventor
Omid C Farokhzad
Nagesh Kilishetti
Shanta Dhar
Stephen J Lippard
Robert S Langer
Pedro M Valencia
Original Assignee
Brigham & Womens Hospital
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital, Massachusetts Inst Technology filed Critical Brigham & Womens Hospital
Publication of IN2012DN05099A publication Critical patent/IN2012DN05099A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN5099DEN2012 2009-12-16 2010-12-16 IN2012DN05099A (enFirst)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28718809P 2009-12-16 2009-12-16
PCT/US2010/060814 WO2011084620A2 (en) 2009-12-16 2010-12-16 Particles for multiple agent delivery

Publications (1)

Publication Number Publication Date
IN2012DN05099A true IN2012DN05099A (enFirst) 2015-10-09

Family

ID=44306061

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5099DEN2012 IN2012DN05099A (enFirst) 2009-12-16 2010-12-16

Country Status (7)

Country Link
US (1) US20130017265A1 (enFirst)
EP (1) EP2512522A4 (enFirst)
JP (1) JP2013514977A (enFirst)
CN (1) CN102791294A (enFirst)
EA (1) EA201290506A1 (enFirst)
IN (1) IN2012DN05099A (enFirst)
WO (1) WO2011084620A2 (enFirst)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115990277A (zh) 2009-07-02 2023-04-21 斯隆-凯特林癌症研究院 基于二氧化硅的荧光纳米颗粒
US12161734B2 (en) 2009-07-02 2024-12-10 Sloan-Kettering Institute For Cancer Research Multimodal silica-based nanoparticles
EP2542057A4 (en) * 2010-03-02 2014-10-15 Vindico Nanobio Technology Inc COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING INFAMOUS DISEASES
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SMT202200321T1 (it) 2010-10-01 2022-09-14 Modernatx Inc Acidi ribonucleici contenenti n1-metil-pseudouracili e loro usi
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9901616B2 (en) 2011-08-31 2018-02-27 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013096596A1 (en) * 2011-12-20 2013-06-27 Latham Keith R Sustained drug release and improved product stability using non-covalent particle coating methods
DK2812372T3 (en) 2012-02-09 2018-11-05 Novus Int Inc HETEROATOM WITH CYCLIC DIMERS
WO2013123298A1 (en) * 2012-02-17 2013-08-22 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
JP2015513913A (ja) 2012-04-02 2015-05-18 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ポリヌクレオチド
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
PL2871973T3 (pl) 2012-07-12 2019-02-28 Novus International Inc. Kompozycje matrycy i warstwy do ochrony środków bioaktywnych
JP2014051478A (ja) * 2012-09-10 2014-03-20 Panasonic Corp 機能性物質、生体活性用薬剤及び機能性物質の生体内への浸透方法、並びに機能性物質放散装置及び空気清浄装置
WO2014059022A1 (en) 2012-10-09 2014-04-17 The Brigham And Women's Hospital, Inc. Nanoparticles for targeted delivery of multiple therapeutic agents and methods of use
WO2014078470A1 (en) * 2012-11-14 2014-05-22 Cornell University Drug delivery compositions and methods targeting p-glycoprotein
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
EP2968621B1 (en) 2013-03-15 2022-08-10 Memorial Sloan-Kettering Cancer Center Multimodal silica-based nanoparticles
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP2983648A4 (en) * 2013-04-09 2016-10-12 Univ Georgia COMBINATION THERAPEUTIC NANOPARTICLES
JP6470740B2 (ja) 2013-06-07 2019-02-13 ザ ジョンズ ホプキンス ユニバーシティ 血管新生およびリンパ管新生依存性疾患の処置のための生体模倣ペプチドおよび生分解性送達プラットフォーム
JP2016523926A (ja) * 2013-07-01 2016-08-12 ユニバーシティ オブ ジョージア リサーチ ファンデーション，インコーポレーテッド 抗癌療法のための細胞ミトコンドリアへの治療剤の正確な送達
US20160158383A1 (en) * 2013-07-26 2016-06-09 The University Of British Columbia Method and device for manufacturing polymer particles containing a therapeutic material
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
MX2016004249A (es) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
CA2931638A1 (en) * 2013-12-12 2015-06-18 University Of Georgia Research Foundation, Inc. Prodrug for release of cisplatin and cyclooxygenase inhibitor
KR20160117440A (ko) 2013-12-31 2016-10-10 메모리얼 슬로안-케터링 캔서 센터 실시간 형광 소스들의 다채널 이미징을 위한 시스템들, 방법들 및 장치
WO2015138992A1 (en) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
WO2015157409A1 (en) * 2014-04-08 2015-10-15 University Of Georgia Research Foundation, Inc. Mitochondria-targeting platinum(iv) prodrug
RU2016144055A (ru) 2014-05-29 2018-07-02 Мемориал Слоун Кеттеринг Кэнсэ Сентр Конъюгаты лекарственного средства с наночастицами
MY203626A (en) 2014-10-03 2024-07-10 Nanotics Llc Compositions and methods for inhibiting the biological activity of soluble biomolecules
CA2985126A1 (en) 2015-05-29 2016-12-08 Cornell University Methods of treatment using ultrasmall nanoparticles to induce cell death of nutrient-deprived cancer cells via ferroptosis
KR20180021805A (ko) * 2015-06-25 2018-03-05 신-낫 프로덕츠 엔터프라이즈 엘엘씨 약제학적 공-결정 조성물 및 이의 용도
EP3334460A4 (en) * 2015-08-13 2019-04-03 Northeastern University BIOMATERIALS FOR COMBINED RADIOTHERAPY AND IMMUNOTHERAPY OF CANCER
CA3001727A1 (en) * 2015-11-18 2017-05-26 Synergy Pharmaceuticals, Inc. Compositions and method for the treatment and detection of colon cancer
AU2016377775A1 (en) * 2015-12-23 2018-07-12 Dana-Farber Cancer Institute, Inc. Immune cell-targeted particles
EP3445385A4 (en) 2016-04-18 2019-11-20 The Trustees of Columbia University in the City of New York THERAPEUTIC GOALS INVOLVED IN THE PROGRESSION OF NON-ALCOHOLIC STEATOHEPATITIS (NASH)
IL299915A (en) 2017-01-04 2023-03-01 Nanotics Llc Methods for assembling cleaning particles
AU2018271781A1 (en) 2017-05-25 2019-12-12 Cornell University Ultrasmall nanoparticles labeled with Zirconium-89 and methods thereof
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions
CA3224718A1 (en) * 2021-06-21 2022-12-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions, methods, and devices for sustained release of an agent
CN114259573B (zh) * 2022-01-06 2023-06-20 中国人民解放军军事科学院军事医学研究院 一种含有胆碱酯酶重活化剂的脑靶向脂质体及其制备方法和用途
CN115382476B (zh) * 2022-07-26 2024-10-22 华东师范大学 一种超小粒径聚合物纳米颗粒的制备方法
WO2025240771A1 (en) * 2024-05-16 2025-11-20 Curadel Surgical Innovations, Inc. Small zwitterionic multimeric targeted drugs and methods of use and manufacture thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2517760B2 (ja) * 1989-05-11 1996-07-24 新技術事業団 水溶性高分子化医薬製剤
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
ES2258495T3 (es) * 1994-04-08 2006-09-01 Qlt Usa, Inc. Composiciones de administracion liquida de farmacos.
KR0180334B1 (ko) * 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
US20020164374A1 (en) * 1997-10-29 2002-11-07 John Jackson Polymeric systems for drug delivery and uses thereof
KR19990085365A (ko) * 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
WO2001047501A1 (en) * 1999-12-29 2001-07-05 Nanodelivery, Inc. Drug delivery system exhibiting permeability control
ATE449596T1 (de) * 2000-08-15 2009-12-15 Univ Illinois Verfahren zur herstellung von mikropartikeln
JP4257697B2 (ja) * 2000-09-26 2009-04-22 株式会社東京大学Ｔｌｏ シスプラチン内包高分子ミセルおよびその使用
US20040047835A1 (en) * 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
US7727969B2 (en) * 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US7371781B2 (en) * 2003-09-22 2008-05-13 University Of Utah Research Foundation Tumor environment-induced ligand-expressing nanocarrier system
AU2003272127A1 (en) * 2003-10-24 2005-05-11 Samyang Corporation Polymeric composition for drug delivery
BRPI0510477B1 (pt) * 2004-04-28 2023-01-17 Angiotech Biomaterials Corporation Método para formar um gel e dispositivo para uso em aplicações médicas
EP1786443B1 (en) * 2004-07-19 2018-06-06 Celator Pharmaceuticals, Inc. Particulate constructs for release of active agents
IL178645A0 (en) * 2006-10-16 2007-02-11 Ariel University Res And Dev C Dendrimeric platform for controlled release of drugs
JP5578655B2 (ja) * 2007-03-02 2014-08-27 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ 微粒子による薬物送達
JP2010526917A (ja) * 2007-05-09 2010-08-05 日東電工株式会社 複数種の薬物を有するポリグルタミン酸塩複合体及びポリグルタミン酸塩−アミノ酸複合体

Also Published As

Publication number Publication date
CN102791294A (zh) 2012-11-21
WO2011084620A3 (en) 2011-11-17
US20130017265A1 (en) 2013-01-17
JP2013514977A (ja) 2013-05-02
WO2011084620A2 (en) 2011-07-14
EP2512522A2 (en) 2012-10-24
EP2512522A4 (en) 2013-09-25
EA201290506A1 (ru) 2013-03-29

Similar Documents

Publication Publication Date Title
IN2012DN05099A (enFirst)
MX2010005889A (es) Derivados de tiofeno como agonistas de s1p1/edg1.
MX2014011815A (es) Composiciones farmaceuticas de liberacion inmediata con propiedades disuasivas de abuso.
MY164607A (en) Solid compositions
WO2013067199A3 (en) Subcutaneous delivery of polymer conjugates of therapeutic agents
ECSP12012148A (es) Composiciones sólidas
MY154909A (en) Novel thiophene derivatives
GEP20156230B (en) Forms of rifaximin and usage thereof
AU2019268096A1 (en) Pharmaceutical compositions comprising modified fucans for use in the treatment of fibrous adhesions and other disorders
AR081678A1 (es) Metodos y composiciones para administracion intratecal de arisulfatasa a
TN2012000195A1 (en) Solid dispersion of rifaximin
MX350447B (es) Composicion farmaceutica de disolucion rapida.
MY153975A (en) Pyridine derivatives as s1p1/edg1 receptor modulators
MX2013002422A (es) Sales de lorcaserina con acidos opticamente activos.
WO2011087548A3 (en) Therapeutic compositions and methods for targeted delivery of active agents
UA102432C2 (ru) Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y
TW200942530A (en) Pyridine compounds
EP2643009A4 (en) COMPOSITION FOR THE RELEASE OF BIODEGRADABLE ACTIVE SUBSTANCES
WO2011126839A3 (en) Compositions and methods for improved retention of a pharmaceutical composition at a local administration site
JO3112B1 (ar) تركيبة دوائية سريعة التحلل
WO2010009140A3 (en) Methods, systems and devices for administration of chlorine dioxide
MX2012010448A (es) Conjugados de carbohidrato-poli aminoacido-farmaco.
WO2013156488A3 (en) Optimised subcutaneous therapeutic agents
WO2011130317A3 (en) Therapeutic agents having reduced toxicity
HK1204962A1 (en) Cyclodextrin-based polymers for therapeutic delivery